PARP1 and breast carcinoma: Luberto and collaborators previously reported [55] a protective effect by the small molecule neutral sphingomyelinase inhibitor GW4869 in MCF7 breast cancer cells reducing nuclear condensation, caspase activation, PARP degradation and trypan blue uptake after apoptotic induction by tumor necrosis factor.